My name is Dr. Temilola Owojuyigb; I work in the Hematology and Blood Transfusion Unit, Ile-Ife, Nigeria. I decided to specialize in Hematology because hematological diseases are not often diagnosed or diagnosed late in affected persons due to a scarcity of experts. Thus, patients either do not get treatment or get treated when many complications have occurred. I am a Consultant Hematologist at the Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC), Ile-Ife. The hospital is in the Southwest of Nigeria. The pioneer Head of the Department of Hematology and Blood Transfusion, OAUTHC, Prof Durosinmi, was able to collaborate with the Max Foundation to make it possible for Nigerians to benefit from the initiative of providing free access to Glivec and other tyrosine kinase inhibitors (TKIs) for the treatment of CML, GIST and other diseases since 2003.
I started my journey in treating and monitoring these patients in 2006 when I began my residency training. Before the TKIs became available in the hospital, we saw about 3 to 5 new CML patients per year, but now we get referrals from all over Nigeria, and we see more than 100 new patients per year. The average age of onset of CML is lower in Nigerians (37 years) than in Europeans and Americans (58 years). The advent of the drugs has led to improved survival and quality of life with a better safety profile and fewer side effects compared to conventional chemotherapy. Most patients become anxious and fearful that their life is about to end and that they will not be able to work or enjoy life. However, due to the availability of the drugs, they have a happy story to tell. They can look back, be thankful, and look forward to the future with hope.
During the COVID-19 lockdown, it was difficult for patients to travel to access treatment; the department initiated a customer-friendly courier service to get the drugs across to the patients.
It has been an excellent experience for me to be an active participant in delivering prompt treatment to patients with the best and most effective drugs free of charge, seeing them survive cancer and live a good quality life. Most patients would not have been able to afford any of the TKIs without the support of the Max Foundation. I also feel good because the standard of care for CML, GIST, and other diseases treatable with TKIs in our hospital and, by extension, in Nigeria, is the same as what is available in the best hospitals in developed countries.
The most significant challenges in my work are 1. When the drugs are not released on time by the Customs or other government agencies or when exorbitant import duties or other payments are charged before the drugs can be removed, this means lifesaving; free drugs will not be available on time for the patients 2, When those traveling from other regions have accidents or other adversities on the way and 3, When patients cannot afford some essential laboratory investigations necessary for monitoring or to decide for a change of medication.
I think Industrial conditions should be favorable for such drugs to be manufactured within the country or to expedite clearance by waiving or reducing charges from government agencies. Making drugs accessible from other regions of Nigeria and Ile-Ife should be considered, as we were available for grants for BCR-ABL1 monitoring and mutation analysis for some patients who cannot afford the tests.
Prompt referrals by primary care physicians, decentralization, involvement of individuals, government, and non-governmental agencies in funding Healthcare and research in Nigeria. I appreciate The Max Foundation for being a bearer of hope and victory against cancer. Max’s memory continues to be a blessing through your work. Cancer has no nationality.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
The Max Foundation is joining Poptivism — a consumer-driven charitable giving program that sells unique PopSocket Grips and donates 50% of the sales of those PopGrips to support a nonprofit’s mission (that’s us!). Please consider purchasing one of our Poptivism PopGrips today! With each purchase, you’ll help expand access to lifesaving cancer treatment the world over.
Each year I am humbled by the extraordinary work and dedication of our 68 Max Global Network partners, hailing from over 50 countries around the world, that tirelessly dedicate their time and resources to improving the lives of people living with cancer worldwide. I would like to take moment to acknowledge just a few of….
The passing of our dear friend, advocate and colleague Ferdinand, has shaken the close-knit global chronic myeloid leukemia (CML) community. CML, a rare form of leukemia that used to be fatal, now is treated with innovative targeted therapies commonly referred to as TKIs. There has been unprecedented global access to these TKIs and this has fostered the development of one of the strongest global patient communities for a rare cancer. Ferdinand, from Nairobi, Kenya, was a loved member of this community.
